Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;157(6):764-6.
doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6.

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

Thomas Prébet, Steven D Gore, Sylvain Thépot, Benjamin Esterni, Bruno Quesnel, Odile Beyne Rauzy, François Dreyfus, Claude Gardin, Pierre Fenaux, Norbert Vey

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

Thomas Prébet et al. Br J Haematol. 2012 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest

TP, NV, ST, CG, PF and SG received research support from Celgene. SG owns stock in Celgene.

Figures

Fig 1
Fig 1
(A) Kaplan Meier estimates of the overall survival after azacitidine (AZA) failure for secondary acute myeloid leukaemia. (B) Survival analysis according to the salvage treatment regimen. The curves represent the survival estimates for the cohort of patients. Each tick mark represents a censored patient. Overall response rate for each treatment group is presented with the number of patients evaluable for response in each cohort. Best supportive care (BSC) included palliative chemotherapy; other treatments included allogeneic transplantation, epigenetic-targeted agents and intensive ‘acute myeloid leukaemia-like’ chemotherapy regimens.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011;117:1463– 1469. - PMC - PubMed
    1. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21:4642–4649. - PubMed
    1. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114:2764–2773. - PMC - PubMed
    1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232. - PMC - PubMed
    1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology. 2010;28:562–569. - PubMed

Publication types

Substances